Acetamido-propanoic Acid Derived Compounds as Protease Inhibitors to Target Coronaviruses

DC FieldValueLanguage
dc.contributor.authorKumar, Arun H.S.-
dc.contributor.authorSharma, Vikram-
dc.date.accessioned2020-05-22T11:52:28Z-
dc.date.available2020-05-22T11:52:28Z-
dc.date.copyright2019 Phcog.Neten_US
dc.date.issued2020-04-
dc.identifier.citationBiology, Engineering, Medicine and Science Reportsen_US
dc.identifier.issn2454-6895-
dc.identifier.urihttp://hdl.handle.net/10197/11379-
dc.description.abstractBackground: Coronavirus infection as evolved into a major pandemic and is currently being treated using established antiviral agents developed for other similar viruses. Considering the frequent mutations rate in this virus, novel drugs will be necessary for effective treatment in future. Hence this study evaluated the potential of acetamido-propanoic acid derived compounds as viral protease inhibitors. Materials and Methods: Using cheminformatics approach novel acetamido-propanoic acid derived compounds were designed and their binding efficacy against the Coronavirus 2019 (Covid-19) protease was tested using Insilco pharmacology. Results: STGYC compounds had physico-chemical features favourable for developing them for potential clinical use. The binding efficacy of STGYC compounds against covid-19 protease was similar to that of favipiravir, which currently being reported to be effective in treating coronavirus infection. Conclusion: STGYC compounds shown favourable features to be further evaluated and developed as viral protease inhibitors.en_US
dc.description.sponsorshipUniversity College Dublinen_US
dc.language.isoenen_US
dc.publishereManuscript Servicesen_US
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.en_US
dc.subjectAntiviral drugsen_US
dc.subjectCoronavirusen_US
dc.subjectCOVID-19en_US
dc.subjectPandemicen_US
dc.subjectProtease inhibitorsen_US
dc.subjectSARS-CoV-2en_US
dc.titleAcetamido-propanoic Acid Derived Compounds as Protease Inhibitors to Target Coronavirusesen_US
dc.typeJournal Articleen_US
dc.internal.authorcontactotherarun.kumar@ucd.ieen_US
dc.statusPeer revieweden_US
dc.identifier.volume5en_US
dc.identifier.issue2en_US
dc.identifier.startpage20en_US
dc.identifier.endpage22en_US
dc.identifier.doi10.5530/bems.5.2.7-
dc.neeo.contributorKumar|Arun H.S.|aut|-
dc.neeo.contributorSharma|Vikram|aut|-
dc.description.othersponsorshipThe Royal Societyen_US
dc.description.othersponsorshipStemcologyen_US
dc.date.updated2020-05-13T20:05:04Z-
dc.identifier.grantidIES\R2\181067 - International Exchanges 2018 Round 2-
dc.identifier.grantidIES/R2/181067-
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:Veterinary Medicine Research Collection
Files in This Item:
File Description SizeFormat 
Coronavirus manuscript draft V2.pdf1.01 MBAdobe PDFDownload
Show simple item record

Page view(s)

213
Last Week
9
Last month
51
checked on Aug 6, 2020

Download(s)

47
checked on Aug 6, 2020

Google ScholarTM

Check

Altmetric


This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.